UrbanDataLab, a South Korean AI platform startup, has successfully raised approximately USD 1.8 million(KRW 2.5 billion) in Series A funding. UrbanDataLab is a technology-driven startup specializing in analyzing cellular-level spatial information and multidimensional data (multi-omics) using AI to identify novel biomarkers that were previously difficult to detect, thereby developing precision medicine solutions.

The funding round was led by Naver Cloud, with participation from The Invention Lab, BDC Labs, and Aseptic Group. The investment reflects high confidence in UrbanDataLab’s proprietary AI technology and its growth potential in the digital pathology and precision medicine markets.

With this capital, UrbanDataLab plans to focus on advancing its AI-based biomarker discovery platform, recruiting key R&D personnel, and strengthening domestic and international partnerships to solidify its technological leadership in the precision medicine sector.

Chi-Sung Ahn, CEO of UrbanDataLab, expressed gratitude, stating, “We deeply appreciate the trust our investors have placed in our technological vision. Moving forward, we aim to leverage AI to contribute to conquering intractable diseases like cancer and accelerate the era of precision medicine, providing optimized treatment opportunities for all patients.”